Decoy Therapeutics Inc.

What they do

Decoy Therapeutics is developing peptide conjugate therapeutics using its proprietary IMP 3 ACT platform, which employs machine learning, AI, and high-speed synthesis to engineer peptide conjugates. The pipeline includes Designable Multi-Antivirals (D-MAV) for respiratory viruses, and legacy Salarius clinical candidates SP-3164 (targeted protein degrader) and seclidemstat (SP-2577, a targeted protein inhibitor). The company also plans to integrate SP-3164 into peptide-based proteolysis targeting chimeras (P-PROTACs). No products are approved for commercial sale, and the company has not generated product revenue.

Revenue drivers

• Product sales — No revenue from product sales to date; the company is pre-clinical stage.
• Other revenue — Reported quarterly revenue of $227,629 for the quarter ended June 30, 2026, likely from non-product sources, but no details in the excerpts.
• Out-licensing potential — Management is seeking strategic alternatives for the SP-2577 program, including potential out-licensing, which could generate future licensing revenue.

Recent performance

For fiscal 2025, net income was $12.5 million, but diluted EPS was $-129.10. Operating cash flow was negative $4.8 million in 2025 and negative $4.5 million in 2024. The latest balance sheet (June 30, 2026) shows total assets of $9.0 million, total liabilities of $4.7 million, and cash & equivalents of $8.3 million. Revenue for the quarter ended June 30, 2026 was $227,629, compared to $0.00 in prior quarters. The company completed a merger and name change in late 2025 and early 2026.

Strategy

The company aims to build a portfolio of peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, using its IMP 3 ACT platform. It plans to integrate the legacy small molecule SP-3164 into P-PROTACs to address 'undruggable' targets. The company is seeking strategic alternatives for SP-2577, including out-licensing. It also completed a private placement in June 2026 to raise capital for its business.

Risks

• No approved products — The company has no products approved for commercial sale and has not generated any product revenue, making it dependent on successful clinical development.
• Negative operating cash flow — Operating cash flow has been negative every year from 2021 to 2025, with a cumulative outflow of approximately $49.9 million.
• Going concern risk — Cash and equivalents of $8.3 million as of June 30, 2026, may be insufficient to fund operations without additional financing, given negative cash flow.
• Nasdaq compliance — An 8-K filed on January 2, 2026 indicated a delisting notice or listing-rule failure, suggesting potential non-compliance with Nasdaq listing requirements.

Outlook

Management expects to continue developing the D-MAV pipeline and integrate SP-3164 into P-PROTACs. They are exploring strategic alternatives for SP-2577, including potential out-licensing. The company raised $3.5 million in a private placement in June 2026, with potential additional milestone-based proceeds from warrants. However, no specific guidance on future revenue or clinical milestones was provided in the excerpts.